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Background: Spinocerebellar ataxia (SCA) and multiple system atrophy-cerebellar type (MSA-C) often present with
similar clinical manifestations in the beginning. Magnetic resonance spectroscopy (MRS) has been proved to be a
useful tool to help differentiate different types of SCA and MSA-C on cross-sectional studies. However, longitudinal
changes of the MRS metabolites in these subjects have never been reported. The purpose of this study was to track
the longitudinal evolution of the MRS metabolites in these patients and to ascertain the correlation between clinical
severity measured by Scale of the Assessment and Rating of Ataxia (SARA) and MRS metabolites.
Results: Significant reductions of NAA/Cr and NAA/Cho in the cerebellar hemispheres in all patients and lower
Cho/Cr in the cerebellar hemispheres in patients with SCA2 or MSA-C were found at all times. At initial assessments,
patients with MSA-C or SCA2 tended to have lower NAA/Cr and Cho/Cr in the cerebellar hemispheres than those
with SCA3 or SCA6. At follow-ups, patients with SCA2 or MSA-C had a lower NAA/Cr in cerebellar hemispheres than
those with SCA3 or SCA6. Patients with MSA-C had a lower NAA/Cr in the vermis and Cho/Cr in the cerebellar
hemispheres than those with SCA2 at the start, and had a lower NAA/Cr in cerebellar hemispheres than those with
SCA2 at follow-ups.
Conclusion: Characteristic patterns of neurodegenerative evolution were observed in patients with disparate SCAs
and MSA-C using MRS and SARA. A continual impairment of neuronal integrity was observed in all groups of
patients. The longitudinal changes of MRS metabolites and SARA scores were most striking in patients with SCA2
and MSA-C. Although the changes in the metabolites on MRS may still be used to help understand the
pathophysiology of ataxia disorders, they are short of being a good biomarker.
Keywords: Proton MRS, SARA, Spinocerebellar ataxias, Multiple system atrophy- cerebellar typeBackground
Spinocerebellar ataxia (SCA) is the most common ataxia
syndrome inherited in an autosomally dominant manner
and may be further categorized into 35 genotypes [1].
Multiple system atrophy-cerebellar type (MSA-C) is the
most common sporadic cerebellar ataxia with a rapidly* Correspondence: bwsoong@ym.edu.tw
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unless otherwise stated.progressive course. The diagnosis of MSA-C is made
according to the clinical features fitting the international
consensus statement [2]. Both types of ataxia disorders
present with similar clinical manifestations initially. An
early and precise diagnosis is important in that it not
only foretells the prognosis, allows for comprehensive
genetic counseling, but also helps design the best clinical
management for each patient. Scale for the Assessment
and Rating of Ataxia (SARA) [3] has been validated to
be a reliable semi-quantitative clinical scale of ataxia
which satisfies accepted criteria of reliability and can betd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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diseases with ataxia.
Magnetic resonance spectroscopy (MRS) provides a
measure of brain chemistry and has been widely used to
non-invasively evaluate in vivo changes of the metabolites
in the brain. Creatine (Cr) provides a measure of energy
stores in the brain. It is very stable and is usually used as a
reference for comparison. N-acetylaspartate (NAA) is a
marker for neuronal integrity or volume [4,5] and a reduc-
tion of NAA denotes a pathological process that adversely
affects neuronal integrity [6-9]. Choline (Cho) is a meas-
ure of cellular turnover, reflecting the content of cytosolic
glycerolphosphocholine and phosphocholine and repre-
senting the products of membrane phosphotidylcholine
breakdown, precursors of choline and acetylcholine syn-
thesis [10]. A reduction in Cho reflects impairment in the
production of cell membranes, the precursor of neuro-
transmitter acetylcholine and acetylcholine itself. NAA/
Cho has been used as a marker for cerebral metabolism
[6,11,12].
In the literature, there have been several cross-
sectional studies on the changes of MRS metabolites in
patients with SCA or MSA-C [13-18], including one
from our group reporting the differences of MRS me-
tabolites between SCAs and MSA-C [18]. MRS has also
been used to longitudinally follow the progression of
other central nervous system disorders, such as demen-
tia [19], mania [20], traumatic brain injury [21] and HIV
encephalopathies [22]. The changes of metabolites in
MRS faithfully correlated with the changes in clinical
severity.
In this paper, we compare the longitudinal changes of
MRS metabolites in the brain and SARA scores in
patients with disparate types of SCAs and MSA-C and
ascertain their correlations.Table 1 Demographic features of the subjects











p# 0.03 0.326 0.195 0.73
SCA2 5 60.6 ±
11.1*
3.7 ± 3.03 8.4 ± 3.13 43.0
SCA3 18 46.3 ±
10.0*
6.14 ± 3.96 10.97 ±
6.28
49.9
SCA6 3 59.0 ±
13.9







4.25 ± 2.20 15.29 ±
6.71
38.7
HC 44 51.1 ±
17.9
– – –
SCA2: Spinocerebellar ataxia type 2; SCA3: Spinocerebellar ataxia type 3; SCA6: Spino
Healthy controls.
*The patients with SCA 3 were significantly younger than those with SCA2 (p = 0.01
#Kruskal-Wallis test.Results
The patients with SCA3 were younger than those with
SCA2 and MSA-C (Table 1). Otherwise, there was no
significant difference between patient groups in terms of
disease duration, SARA scores at the time when the first
or the second MRS assessment was performed, or the
time interval in between two assessments.
The MRS of patients with different SCAs and MSA-C
were demonstrated in Figure 1.Patients with MSA-C
In patients with MSA-C, the NAA/Cr, Cho/Cr and
NAA/Cho in both the cerebellar hemispheres and ver-
mis were significantly reduced (p < 0.001) at both MRS
assessments, as compared with those of the healthy
controls (Table 2).Patients with SCA
In all types of SCAs studied, the NAA/Cr in the cerebel-
lar hemispheres and vermis and NAA/Cho in the cere-
bellar hemispheres were significantly reduced (p < 0.05)
at both assessments (Table 2).
In patients with SCA2, the Cho/Cr in the cerebellar
hemispheres was significantly reduced (p < 0.05) at both
MRS assessments (Table 2) and in the vermis only at the
second MRS assessment, as compared with the healthy
controls.
In patients with SCA3, NAA/Cho in the vermis
appeared consistently reduced and Cho/Cr in the cere-
bellar hemisphere became significantly reduced than
healthy controls at 2nd MRS assessment (p < 0.05).
(Table 2) In patients with SCA6, NAA/Cho appeared
significantly reduced in the vermis at initial assessment.





Interval in between 2 MRS
assessments (months)
6 0.114 0.680
± 15.47 17.13 ±
7.1
38.63 ± 13.21
1 ± 23.82 15.28 ±
5.23
43.78 ± 21.74
5 ± 15.2 19.0 ±
1.41
34.5 ± 17.68
± 12.33 22.35 ±
7.02
34.3 ± 12.82
cerebellar ataxia type 6; MSA: Multiple system atrophy- cerebellar type; HC:
4) or MSA-C (p = 0.001).
Figure 1 The MR spectroscopy of the patients at the initial (upper) and follow-up (lower) assessments. (A) healthy controls, (B) SCA2, (C) SCA3,
(D) SCA6 and (E) MSA-C.
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Table 2 Comparison of 1H MRS metabolites between the patients with SCA, MSA-C and controls and between 2
assessments in each group
Metabolites on The 1st MRS* vs.
controls
The 2nd MRS* vs.
controls
1st vs. 2nd
MRS#the 1st MRS the 2nd MRS
Cerebellar hemispheres NAA/Cr
SCA2 0.65 ± 0.10 0.72 ± 0.06 0.000 0.000 0.113
SCA3 0.88 ± 0.10 0.85 ± 0.08 0.000 0.000 0.073
SCA6 0.83 ± 0.07 0.87 ± 0.08 0.001 0.014 0.440
MSA-C 0.58 ± 0.14 0.62 ± 0.23 0.000 0.000 0.331
HC 1.00 ± 0.12 - - - -
Cho/Cr
SCA2 0.58 ± 0.07 0.62 ± 0.05 0.001 0.019 0.031
SCA3 0.68 ± 0.09 0.65 ± 0.08 0.392 0.027 0.098
SCA6 0.69 ± 0.08 0.65 ± 0.04 0.710 0.279 0.116
MSA-C 0.50 ± 0.10 0.52 ± 0.14 0.000 0.000 0.955
HC 0.70 ± 0.09 - - - -
NAA/Cho
SCA2 1.14 ± 0.27 1.16 ± 0.16 0.004 0.000 0.796
SCA3 1.30 ± 0.17 1.31 ± 0.15 0.000 0.001 0.768
SCA6 1.23 ± 0.15 1.34 ± 0.10 0.008 0.174 0.113
MSA-C 1.17 ± 0.29 1.21 ± 0.28 0.000 0.000 0.263
HC 1.45 ± 0.19 -
Vermis NAA/Cr
SCA2 0.74 ± 0.05 0.70 ± 0.09 0.000 0.003 0.421
SCA3 0.82 ± 0.07 0.80 ± 0.08 0.002 0.000 0.205
SCA6 0.79 ± 0.06 0.76 ± 0.06 0.024 0.043 0.126
MSA-C 0.63 ± 0.08 0.64 ± 0.08 0.000 0.000 0.966
HC 0.90 ± 0.11 - - - -
Cho/Cr
SCA2 0.61 ± 0.08 0.55 ± 0.06 0.062 0.003 0.233
SCA3 0.66 ± 0.07 0.65 ± 0. 08 0.433 0.194 0.910
SCA6 0.70 ± 0.03 0.65 ± 0.06 0.494 0.463 0.451
MSA-C 0.54 ± 0.06 0.50 ± 0.11 0.000 0.000 0.178
HC 0.68 ± 0.07 - - - -
NAA/Cho
SCA2 1.22 ± 0.19 1.28 ± 0.07 0.174 0.380 0.833
SCA3 1.25 ± 0.13 1.22 ± 0.13 0.072 0.002 0.170
SCA6 1.13 ± 0.10 1.17 ± 0.02 0.024 0.065 0.766
MSA-C 1.16 ± 0.08 1.31 ± 0.24 0.000 0.991 0.083
HC 1.32 ± 0.18 -
SCA2: Spinocerebellar ataxia type 2; SCA3: Spinocerebellar ataxia type 3; SCA6: Spinocerebellar ataxia type 6; MSA-C: Multiple system atrophy-cerebellar type; HC:
Healthy controls.
*Mann–Whitney test, p value.
#Pair-t test, p value.
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and MSA-C
At the first MRS assessment (Table 3), patients with
MSA-C had a significantly lower NAA/Cr and Cho/Crin the cerebellar hemispheres and vermis than those
with SCA3 or SCA6, and a lower NAA/Cho in the cere-
bellar hemispheres than those with SCA3. Furthermore,
patients with SCA2 had a significantly lower NAA/Cr
Table 3 The differences in MRS metabolites between
patient groups at the 1st MRS assessment
Disease SCA3* SCA6* MSA-C*
Cerebellar hemispheres NAA/Cr SCA2 0.000 0.004 0.155
SCA3 - 0.356 0.000
SCA6 - - 0.000
Cho/Cr SCA2 0.010 0.039 0.035
SCA3 - 0.985 0.000
SCA6 - - 0.002
NAA/Cho SCA2 0.236 0.606 0.743
SCA3 - 0.356 0.018
SCA6 - - 0.401
Vermis NAA/Cr SCA2 0.037 0.297 0.013
SCA3 - 0.487 0.000
SCA6 - - 0.024
Cho/Cr SCA2 0.256 0.180 0.064
SCA3 - 0.252 0.001
SCA6 - - 0.011
NAA/Cho SCA2 0.730 0.456 0.493
SCA3 - 0.158 0.092
SCA6 - - 0.665
SCA2: Spinocerebellar ataxia type 2; SCA3: Spinocerebellar ataxia type 3; SCA6:
Spinocerebellar ataxia type 6; MSA-C: Multiple system atrophy- cerebellar type.
*Mann–Whitney test, p-value.
Table 4 The differences in MRS metabolites between
patient groups at 2nd MRS assessment
Disease SCA3* SCA6* MSA-C*
Cerebellar hemispheres NAA/Cr SCA2 0.001 0.014 0.017
SCA3 - 0.538 0.000
SCA6 - - 0.022
Cho/Cr SCA2 0.197 0.393 0.055
SCA3 - 0.979 0.001
SCA6 - - 0.067
NAA/Cho SCA2 0.026 0.089 0.617
SCA3 - 0.456 0.077
SCA6 - - 0.202
Vermis NAA/Cr SCA2 0.064 0.355 0.356
SCA3 - 0.526 0.000
SCA6 - - 0.085
Cho/Cr SCA2 0.017 0.064 0.480
SCA3 - 0.880 0.003
SCA6 - - 0.133
NAA/Cho SCA2 0.484 0.165 0.777
SCA3 - 0.233 0.202
SCA6 - - 0.390
SCA2: Spinocerebellar ataxia type 2; SCA3: Spinocerebellar ataxia type 3; SCA6:
Spinocerebellar ataxia type 6; MSA-C: Multiple system atrophy-cerebellar type.
*Mann–Whitney test, p value.
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with SCA3 or SCA6.
At the second MRS assessment (Table 4), patients with
MSA-C still had lower NAA/Cr, Cho/Cr in the cerebel-
lar hemispheres and vermis than those with SCA3 and
lower NAA/Cr in the cerebellar hemispheres than those
with SCA2 and SCA6. Patients with SCA2 continued to
have lower NAA/Cr in the cerebellar hemispheres than
those with SCA3 or SCA6.
Longitudinal changes in the MRS metabolites
There was no significant difference in the MRS metabo-
lites between initial and follow up assessments in the
study groups (Table 2), except for an increase of Cho/Cr
with time in the cerebellar hemispheres in patients
with SCA2 (p = 0.031) (Table 2). Furthermore, there was
no difference in the monthly changes of metabolites
between different groups of patients (Table 5 and
Figure 2).
Longitudinal changes in the SARA scores
There were significant increases of SARA scores with
time in patients with SCA2 (p = 0.031), SCA3 (p < 0.001)
and MSA-C (p < 0.001), but not in SCA6 (p = 0.318)
(Table 6). Moreover, if we compared the changes of
SARA on a monthly basis, patients with MSA-C and
SCA2 stood out and seemed to have a faster progressionthan those with SCA3 or SCA6 (Table 6, Figure 2G),
although the difference had not reached a statistical
significance.
The correlation between the changes of MRS metabolites
and SARA scores
The changes of NAA/Cr (R = −0.332, P < 0.001 in the
cerebellar hemispheres; R = −0.521, P < 0.001 in the ver-
mis) and Cho/Cr (R = −0.380; P < 0.001 in the cerebellar
hemispheres; R = −0.529, P < 0.001 in the vermis) were
inversely correlated with the changes of SARA scores
(Figure 3).
Discussion
To our knowledge, this is the first study designed to
evaluate the longitudinal changes of metabolites on MRS
in conjunction with the clinical severity measured with
SARA in patients with ataxia syndromes. Our study has
several strengths. First, the same MR instrument and
study protocol were used throughout. Second, the clin-
ical severity was evaluated uniformly by a single board-
certified neurologist who is experienced in evaluating
ataxia with the same valid assessment scale, SARA.
Third, the disease duration and clinical severity at two
assessments were similar across different diseases.
In this study, a continual impairment in neuronal in-
tegrity, as indicated by the reduction in NAA/Cr in the
Table 5 The monthly changes of MRS metabolites in different groups of patients╥
Cerebellar hemispheres Vermis
NAA/Cr Cho/Cr NAA/Cho NAA/Cr Cho/Cr NAA/Cho
p# 0.471 0.168 0.261 0.693 0.269 0.273
SCA2 0.09 ± 0.17 0.13 ± 0.14 −0.08 ± 0.28 −0.25 ± 0.53 −0.18 ± 0.23 −0.08 ± 0.68
SCA3 −0.04 ± 0.22 −0.04 ± 0.26 0.01 ± 0.61 −0.07 ± 0.20 0.05 ± 0.21 −0.22 ± 0.37
SCA6 0.06 ± 0.22 −0.11 ± 0.16 0.27 ± 0.44 −0.18 ± 0.13 −0.16 ± 0.16 0.00 ± 0.45
MSA-C 0.14 ± 0.59 0.02 ± 0.37 0.33 ± 1.14 0.03 ± 0.32 −0.14 ± 0.36 0.51 ± 0.86
SCA2: Spinocerebellar ataxia type 2; SCA3: Spinocerebellar ataxia type 3; SCA6: Spinocerebellar ataxia type 6; MSA-C: Multiple system atrophy- cerebellar type.
╥Data are presented as 100X MRS ratios.
#Kruskal-Wallis test.
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initial and follow-up assessments was found in all groups
of patients. Over the timespan of 2–4 years, not much
difference in MRS metabolites was observed between
two MRS assessments (Table 2) in all SCA subgroups
and MSA-C, suggesting that MRS metabolites are not
sensitive enough markers to track the changes in cere-
bellar metabolism over the limited time span of follow-
up (Table 2). Further study with larger sample sizes
might be needed to validate these observations. On the
other hand, SARA scores faithfully reflected the deteri-
oration in severity of SCA2, SCA3 and MSA-C over the
time span (Table 6), implicating that SARA qualifies as a
more sensitive marker to gauge the progression of cere-
bellar ataxias. Nevertheless, the changes of NAA/Cr and
Cho/Cr in the cerebellar hemispheres and vermis some-
how still inversely correlated with the changes in SARA
scores. The evolution of different metabolites on MRS
could still, to a certain degree, help understand the
pathophysiology of the disease.
MSA-C
In general, patients with MSA-C tended to have a worse
neuronal integrity and less production of cell mem-
branes than those with SCA3 or SCA6 at the first MRS
assessment (Tables 2 and 3). With time, the differences
remained similar at follow-ups (Table 4), suggesting a
persistent and more severe disruption in the neuronal
and membrane integrity in MSA-C. MSA-C is a rapidly
progressive neurodegenerative disease manifesting ataxia
and autonomic dysfunction [23]. Our previous cross-
sectional study in patients with MSA-C also corrobo-
rated these observations [18].
MSA-C and SCA2 are two relentlessly and rapidly
progressive diseases manifesting ataxia with neuronal
drop-outs and impairment of membrane synthesis. Lac-
tate peak and myo-inositol were previously proposed to
be indicators to differentiate SCA2 from MSA-C
[14-16]. In this study, we found that, at the early stage of
the diseases, the MRS features were similar between
MSA-C and SCA2. As disease progressed, the differentspeed of changes in Cho/Cr and NAA/Cr in the cerebel-
lar hemispheres might help differentiate MSA-C from
SCA2 (Table 4).
SCA
In line with previous reports [15,16], patients with SCA2
have a more severe impairment in neuronal integrity,
given the lower NAA/Cr in the cerebellar hemispheres
than those with SCA3 or SCA6 at the start and at the
follow-up assessment, even being of similar clinical
severity (Tables 2, 3 and 4). The SARA scores increased
significantly in SCA2 and SCA3 but not in SCA6 during
the period of follow up (Tables 1 and 6). Although there
was little difference in the monthly changes of SARA
scores between subtypes of SCAs, the change was still
higher in SCA2 (Table 6). Pathological studies in the
past have revealed, in SCA2, a marked loss of Purkinje
cells in the cerebellar cortex and a loss of myelinated
fibers in the cerebellar peduncles and white matter, spar-
ing the dentate nucleus, and the neuronal degeneration
preceded the onset of clinical symptoms [24]. While a
prominent spinopontine degeneration with a relative
sparing of the olivocerebellar regions in SCA3 [25] and a
pure cerebellar degeneration with a loss of Purkinje cells
in the cerebellar cortex in SCA6 [26,27] were observed.
The synaptic loss in the cerebellum and brainstem is
most severe in SCA2 [28,29]. The MRS changes ob-
served by us are corroborated by the pathological
changes.
The disease progression reflected by the monthly
changes of SARA scores was most severe in SCA2,
MSA-C, followed by SCA3 and SCA 6. Similar results
have been documented in our earlier report [30].
Interval changes
Progressive reduction in the cerebellar volume, correlat-
ing with disease duration and age, has been documented
in patients with MSA-C [31], SCA2 [32], SCA3 [33] and
SCA6 [34]. In SCA2, the presence of pre-symptomatic
region-specific atrophy was observed and a possible
developmental component to the pathomechanisms was
Figure 2 Monthly changes of the MRS metabolites and the SARA scores. (A) NAA/Cr in the cerebellar hemispheres, (B) Cho/Cr in the
cerebellar hemispheres, (C) NAA/Cho in the cerebellar hemispheres, (D) NAA/Cr in the vermis, (E) Cho/Cr in the vermis, (F) NAA/Cho in the
vermis. (G) Changes of total SARA scores.
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MRS changes in SCA2 when the clinical severity repre-
sented by SARA scores is still low and disease duration
remains short.The limitations of this study are, first, the sizes of the
patients were relatively small, especially in SCA2 and
SCA6. The small patient numbers could be the reason
contributing to the lack of significance in disease
Table 6 The monthly changes of SARA scores in different groups of patients
SARA score at the 1st assessment SARA score at the 2nd assessment 1st vs. 2nd SARA scores@ Monthly changes of SARA
p# 0.195 0.114 0.343
SAC2 8.4 ± 3.13 17.13 ± 7.1 0.031 0.31 ± 0.24
SAC3 10.97 ± 6.28 15.28 ± 5.23 0.000 0.15 ± 0.10
SAC6 12.5 ± 2.65 19.0 ± 1.41 0.318 0.15 ± 0.05
MSA-C 15.29 ± 6.71 22.35 ± 7.02 0.000 0.26 ± 0.18
#Kruskal-Wallis test.
@Pair-t test, p value.
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heterogeneities by recruiting only patients who had their
first MRS examination at a disease duration less than
12 months. Furthermore, the MRS metabolites from
both cerebellar hemispheres were averaged for the ease
of analyses, thus the data of MRS from the cerebellar
hemispheres should actually be twice as many as thoseFigure 3 The correlation between SARA and MRS metabolites. (A) NA
cerebellar hemispheres vs. SARA, (C) NAA/Cr in the vermis vs. SARA and (Dfrom the vermis. Hence, the reason that some differ-
ences of MRS in patient groups were observed only in
the cerebellar hemispheres, but not in the vermis, could
likely be attributed to the limited patient numbers.
Third, we only focused on the metabolites in the cere-
bellar hemispheres and vermis. Fourth, we only corre-
lated the metabolites on MRS with total SARA scores.A/Cr in the cerebellar hemispheres vs. SARA, (B) Cho/Cr in the
) Cho/Cr in the vermis vs. SARA.
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SARA might be different [30]. Further studies with MRS
in a larger cohort, addressing also the changes of metab-
olites in the other regions of the brain while correlating
the changes between MRS metabolites and different
compartments of SARA, would be desirable to help
unravel the pathophysiology of the SCAs and MSA-C.
Conclusion
Different patterns of neurodegeneration with impairment
in neuronal integrity and defective membrane activities
were observed in patients with SCAs and MSA-C in this
longitudinal study. Although the changes on MRS nega-
tively correlated with clinical severity (Figure 2), MRS does
not seem to be a sensitive marker to assess the progress of
ataxia syndromes. Nevertheless, the longitudinal changes
of MRS and SARA scores in SCA2, SCA3 and MSA-C
were different, both in the beginning and on the follow-
up’s. Changes in MRS metabolites may still be used to




This study was approved by the Institutional Review
Board of Taipei Veterans General Hospital, Taipei, Taiwan.
Patients who had undergone SARA and MR spectroscopy
at least twice over a period of 10 years were enlisted. The
interval between evaluations with SARA and the MR
spectroscopy must be approximately within 3 months.
From March 2004 to January 2014, a total of 47 patients
with either one of the SCAs or MSA-C were studied se-
quentially in the afore-mentioned manner. Among them,
38 patients had their first MRS assessment with a disease
duration less than 12 months and the follow-up MRS after
one year. Among them, 5 were molecularly identified to
be SCA2, 18 SCA3, and 3 SCA6. Twelve patients met the
criteria of MSA-C. Forty-four healthy individuals without
any history of neurological diseases served as controls.
The MRS features in the basal ganglion were validated
according to the normal data proposed by Brain Ross and
Else Rubaek Danielsen [35]. The demographic features of
the study subjects are listed in Table 1.
Images and spectroscopic acquisition
Brain MRI and MRS were performed using a 1.5-T system
(Signa EXCITE, GE Medical Systems, Milwaukee, WI). The
MRI protocol consisted of an axial T1-weighted three-
dimensional fast-spoiled gradient recalled acquisition in
steady state images (TR 8.58 msec, TE 3.62 msec, inversion
time [TI] 400 msec, voxel resolution 0.75X0.75X1.5 mm3)
and an axial T2 fast spin-echo sequence [TR 4000 msec,
TE 256.5 msec, voxel resolution 348X512].After MR imaging, proton MRS was recorded in the
cerebellar hemispheres and vermis by using single-voxel
stimulated echo acquisition mode sequence (3000/15/13.7/
96 [TR/TE/mixing time/excitations], spectral width =
2500 Hz, number of points = 2048, voxel resolution =
2 cm × 2 cm × 2 cm). The voxel of interest (VOI) in each
subject was placed in a uniform manner by the same inves-
tigator (JFL). Care was taken to avoid cerebrospinal fluid
space within the VOIs. The peak areas for N-acetyl aspar-
tate (NAA) at 2.02 parts per million (ppm), Creatine (Cr) at
3.03 ppm, and Choline (Cho) at 3.22 ppm were measured
using the Functool provided by the MR company (GE XVi,
Milwaukee, WI). Peak integral values were expressed
relative to the Cr peak. Metabolite intensity ratios were
automatically calculated at the end of each single voxel
acquisition including NAA/Cr and Cho/Cr. The NAA/Cho
ratio was also calculated for comparison. MRS results with
full width at half maximum (FWHM) > 6 Hz were disquali-
fied from the MRS analyses to ensure high quality.
Statistical analyses
Comparisons of the age at examination between the pa-
tient groups and healthy controls and comparison of the
disease duration and the SARA scores at first and second
evaluations between the patient groups were performed
using nonparametric analyses (Kruskal-Wallis H test)
given that some of the sample sizes were small and the as-
sumption of a Gaussian distribution was not appropriate.
Similarly, given the non-Gaussian distribution of the MRS
parameters, comparison of the metabolites on MRS
(NAA/Cr, Cho/Cr and NAA/Cho in the cerebellar hemi-
spheres or vermis) between different groups of patients
and healthy controls, between patients of disparate types
of SCA and MSA-C, between patients with different types
of SCA at initial and follow-up MRS assessments, and
comparison of the monthly changes of metabolites on
MRS and SARA scores were all performed using the non-
parametric Mann–Whitney U-test. The interval changes
of metabolites on MRS and SARA scores were evaluated
by pair-t test. The correlation between metabolites on
MRS and SARA scores was assessed with Pearson’s correl-
ation coefficient. Differences were considered significant
at p <0.05. Data are given as mean ± standard deviation.
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